Medical Condition News

RSS

Web conference to analyze latest trends, developments in the European melanoma skin cancer market

There are only two FDA/EMEA approved drugs currently available for treating advanced melanoma. The available drugs, however, are not completely effective and have adverse effects. Unmet needs of patients, especially those with advanced melanoma are therefore quite high and have led to a low drug adoption and market growth over the years. The future looks brighter though, with a few promising drugs in pipeline for advanced melanoma.

18 May 2010

Human stem cells restore alveolar epithelial tissue after E. coli endotoxin-induced ALI: Researchers

Human stem cells administered intravenously can restore alveolar epithelial tissue to a normal function in a novel ex vivo perfused human lung after E. coli endotoxin-induced acute lung injury, according to research from the University of California San Francisco.

18 May 2010

Study reveals association between depression and coronary spasm

A study published in the current issue of Psychotherapy and Psychosomatics explores the relationship between depression and coronary artery spasm.

18 May 2010

Adults with newly diagnosed type 1 diabetes recruited for Protege Encore clinical trial

Dr. Bruce Bode announced today that he is now recruiting adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes.

18 May 2010

KemPharm enters Supply Agreement with Johnson Matthey for KP201 hydrocodone prodrug for acute pain

KemPharm, Inc. today announced that it has entered into an exclusive Supply Agreement with Johnson Matthey Inc., for the manufacture of the active pharmaceutical ingredient (API), KP201, KemPharm's novel hydrocodone prodrug for acute pain. KP201 was identified utilizing KemPharm's proprietary ligand activated therapy (LAT) approach.

18 May 2010

IDEV launches SUPERA VERITAS Peripheral Vascular System in Europe

IDEV Technologies, Incorporated, (IDEV) an emerging leader in the development and marketing of minimally invasive medical technologies, today announced the European launch of the SUPERA VERITAS™ Peripheral Vascular System, a novel and innovative stent delivery system designed to be reliable, easy to use and precise. The SUPERA VERITAS system was formally launched in the first quarter of 2010 at the Leipzig Interventional Course (LINC) 2010 conference in Leipzig, Germany.

18 May 2010

Study confirms genetic overlap for susceptibility to COPD and lung cancer

New research shows genes that make smokers more likely to develop chronic obstructive pulmonary disease (COPD), or emphysema, are also closely linked to an increased likelihood of developing lung cancer, according to studies presented today at the American Thoracic Society's annual meeting.

18 May 2010

Millions of Americans continue to risk losing their hearing each day, warns audiologist

May is Better Hearing Month, but millions of Americans are continuing to needlessly risk losing their hearing each day, warns audiologist Dr. Cindy Beyer. "Almost all hearing loss is due to the aging process or to noise, but only noise-induced hearing loss can be prevented," says Dr. Beyer, senior vice president of HearUSA, a nationwide provider of hearing care and hearing aids.

18 May 2010

ev3 files final module of PMA for Pipeline Embolization Device

ev3 Inc., a global endovascular device company, today announced that it has filed the final module of its Premarket Approval application with the U.S. Food and Drug Administration for the Pipeline Embolization Device. This final module, containing a comprehensive review of the clinical data, completes the PMA application to the FDA.

18 May 2010

Sleep apnea increases insulin resistance: Study

Sleep apnea may cause metabolic changes that increase insulin resistance, according to researchers from the University of Pittsburgh Medical Center. The intermittent hypoxia associated with sleep apnea causes a distinct drop in insulin sensitivity in mice, even though chronic hypoxia, such as that associated with high altitude, did not.

18 May 2010

Combination therapy proves to be effective treatment for lethal form of leukemia: Research

New research discovers a combination of drugs that may prove to be a more effective treatment for a lethal form of leukemia. The study, published by Cell Press in the May issue of the journal Cancer Cell, reports that the new therapeutic strategy effectively targets notoriously intractable leukemia stem cells that often escape standard treatment and are a main factor in disease relapse.

18 May 2010

IMUC, Torrey Pines Institute identify peptides that generate CD-133 specific T-cells

ImmunoCellular Therapeutics, a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that the Company and Torrey Pines Institute for Molecular Studies in San Diego, CA have identified several peptides which can generate CD-133 specific T-cells. CD-133 is found in high abundance on cancer stem cells ("CSCs") which makes it promising for immunological targeting.

18 May 2010

New research shows link between mental health and creativity

New research shows a possible explanation for the link between mental health and creativity. By studying receptors in the brain, researchers at Karolinska Institutet have managed to show that the dopamine system in healthy, highly creative people is similar in some respects to that seen in people with schizophrenia.

18 May 2010

LIFEDGE delivery system from Stand-By Systems ready for pilot scale production

Emerging Healthcare Solutions, Inc. disclosed that the Company has received documents from Stand-By Systems affirming that their revolutionary LIFEDGE prototype is now complete and ready for pilot scale production. EHSI recently executed an option with Stand-By Systems, owner of the new FDA approved SBS 1615 catalytic oxygen generator and associated systems.

18 May 2010

Remote Presence hospital networks to accelerate patient's access to clinical stroke experts

InTouch Health, the world leader in Remote Presence Total Telemedicine solutions, is advancing stroke care by developing Remote Presence hospital networks that accelerate a patient's access to clinical stroke experts. To date, the Company has more than 25 stroke and multispecialty care networks comprised of over 300 hospital locations.

18 May 2010

Regular consumption of pistachios lowers risk of CHD: Study

A new nut and blood lipid study published on May 10, 2010, in Archives of Internal Medicine, led by Dr. Joan Sabate and colleagues at Loma Linda University (Loma Linda, Calif.), confirms that eating nuts, like pistachios, have a total and LDL (bad)-cholesterol-lowering effect, supporting the evidence that regular nut consumption can lower the risk of coronary heart disease.

18 May 2010

REVEAL risk score calculator provides innovative approach to better understand PAH

Actelion Ltd announced today that findings from the REVEAL Registry have confirmed the clinical utility of the REVEAL risk score calculator, a new tool designed to predict 1-year survival in patients with pulmonary arterial hypertension according to data presented at the American Thoracic Society's Annual International Conference.

18 May 2010

Combining medicine switch with cognitive behavioral therapy can reduce symptoms of depression: Study

More than one-third of teenagers with treatment-resistant depression - many of whom had been depressed for more than two years - became symptom-free six months after switching their medication or combining a medicine switch with cognitive behavioral therapy during a multicenter study led by UT Southwestern Medical Center researchers.

18 May 2010

Cerenis' CER-001 Phase 1 study data supports continued clinical development for acute coronary syndromes

Cerenis Therapeutics, a biopharmaceutical company focused on discovering and developing novel HDL therapies, today announced the completion of a Phase 1 study of the Company's CER-001 investigational product candidate to treat patients with acute coronary syndromes. Results of the completed study provide evidence that the investigational therapy was safe and well-tolerated at all dose levels evaluated, including those intended for future clinical development.

18 May 2010

New book offers practical knowledge on celiac disease, gluten-related disorders

A new book from the American Gastroenterological Association offers broad and practical knowledge on celiac disease and gluten-related disorders, empowering those who are undiagnosed and those living with the disease to achieve the best possible health and well-being.

18 May 2010

Medical Condition News

Web conference to analyze latest trends, developments in the European melanoma skin cancer market

Human stem cells restore alveolar epithelial tissue after E. coli endotoxin-induced ALI: Researchers

Study reveals association between depression and coronary spasm

Adults with newly diagnosed type 1 diabetes recruited for Protege Encore clinical trial

KemPharm enters Supply Agreement with Johnson Matthey for KP201 hydrocodone prodrug for acute pain

IDEV launches SUPERA VERITAS Peripheral Vascular System in Europe

Study confirms genetic overlap for susceptibility to COPD and lung cancer

Millions of Americans continue to risk losing their hearing each day, warns audiologist

ev3 files final module of PMA for Pipeline Embolization Device

Sleep apnea increases insulin resistance: Study

Combination therapy proves to be effective treatment for lethal form of leukemia: Research

IMUC, Torrey Pines Institute identify peptides that generate CD-133 specific T-cells

New research shows link between mental health and creativity

LIFEDGE delivery system from Stand-By Systems ready for pilot scale production

Remote Presence hospital networks to accelerate patient's access to clinical stroke experts

Regular consumption of pistachios lowers risk of CHD: Study

REVEAL risk score calculator provides innovative approach to better understand PAH

Combining medicine switch with cognitive behavioral therapy can reduce symptoms of depression: Study

Cerenis' CER-001 Phase 1 study data supports continued clinical development for acute coronary syndromes

New book offers practical knowledge on celiac disease, gluten-related disorders

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News